v3.25.4

Collaboration Agreements (Details) $ in Millions | 1 Months Ended | 12 Months Ended
--- | --- | ---
Nov. 30, 2022 item | Dec. 31, 2025 USD ($)
LigaChem Biosciences |  |
Collaboration Agreements |  |
Additional receivable on collaboration agreements, finalization of cost sharing |  | $ 0.4
Research Collaboration and Co-Development Agreement |  |
Collaboration Agreements |  |
Maximum number of antibody drug conjugates to be developed | item | 3 |
Collaboration agreements cost sharing percentage (as a percent) | 50.00% | 50.00%
Collaboration arrangement reduction in expenses |  | $ 2.5

X
- Definition Amount of additional receivable on finalization of costs sharing terms under collaborative agreements. + References No definition available. + Details
Name: | nxtc_CollaborationAgreementsAdditionalReceivableOnFinalizationOfCostSharingTerms
Namespace Prefix: | nxtc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the collaboration agreements cost sharing percentage. + References No definition available. + Details
Name: | nxtc_CollaborationAgreementsCostSharingPercentage
Namespace Prefix: | nxtc_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of collaborative arrangement reduction in expense. + References No definition available. + Details
Name: | nxtc_CollaborativeArrangementReductionInExpenseAmount
Namespace Prefix: | nxtc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the maximum number of antibody drug conjugates to be developed. + References No definition available. + Details
Name: | nxtc_MaximumNumberOfAntibodyDrugConjugatesToBeDeveloped
Namespace Prefix: | nxtc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=nxtc_LegochemBiosciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nxtc_ResearchAndDevelopmentCollaborativeAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |